In vitro and in vivo models have shown that baicalein reduces the impact of IBD by inhibiting the COX-2 activity and decreases the phosphorylation of Ikappa kinase (IKK)-β degrading the Ikappa-beta-alfa (IκΒα) 69, also ameliorating UC by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s 70 and through the inhibition of TLR4/MyD88 signaling cascade as well as inactivation of NLRP3 inflammasome 71. This evidence concerns the gene MYD88 and irritable bowel syndrome.